NewsBenzingaオルカセラピューティクスは、中等度から重度のプラーク乾癬患者を対象としたORKA-001の第2A相試験EVERLAST-Aの28週目の結果を発表。ORKA-001は28週目までに有利な安全性と耐容性のプロファイルを維持。エバーラスト-Bの16週データは2026年第4四半期に期待される。 オルカセラピューティクスは、中等度から重度のプラーク乾癬患者を対象としたORKA-001の第2A相試験EVERLAST-Aの28週目の結果を発表。ORKA-001は28週目までに有利な安全性と耐容性のプロファイルを維持。エバーラスト-Bの16週データは2026年第4四半期に期待される。 Benzinga 2026.09.23 11:08 (GMT+0) Open on Benzinga Other news Allied Gold Advances Exploration And Design Activities At Tsenge Trend To Expand Additional Mining Area; Affirms Plan For Base Dividend Starting In 2027 And Normal Course Issuer Bid For Up To 10% Of Public Float Global-E Online Stock Is Falling Wednesday: What's Going On? Grifols Presents New Real-World Evidence Data From AMBAR Program, Contributing To Ongoing Research Evaluating Use Of TPE With Albumin Replacement In Patients With Alzheimer’s Disease HC Wainwright & Co. Maintains Buy on Cerenome, Raises Price Target to $7 Streamex Launches Yield Bearing Gold Asset GLDY As Available Asset To IRA Account Holders Of Equity Trust Company As Its First Tokenized Asset HC Wainwright & Co. Maintains Buy on LifeMD, Lowers Price Target to $6
Allied Gold Advances Exploration And Design Activities At Tsenge Trend To Expand Additional Mining Area; Affirms Plan For Base Dividend Starting In 2027 And Normal Course Issuer Bid For Up To 10% Of Public Float
Grifols Presents New Real-World Evidence Data From AMBAR Program, Contributing To Ongoing Research Evaluating Use Of TPE With Albumin Replacement In Patients With Alzheimer’s Disease
Streamex Launches Yield Bearing Gold Asset GLDY As Available Asset To IRA Account Holders Of Equity Trust Company As Its First Tokenized Asset